Further, the exploration of valine–niclosamide’s activity against NF-kB, STAT3, KRAS, and other oncogenic pathways that demonstrate rebound activity following AR-KO is necessary in HCC, PCa, and other cancers to demonstrate the maintenance of key types of activity across cancer types. Here, KRAS is linked to hepatocellular carcinoma.